ABOUT IMMUNO
Immuno Technologies, Inc (ITi) is a Memphis-TN based company focused on preclinical research in preventatives (vaccines, monoclonal antibody therapies) and diagnostic assays for Lyme disease and leptospirosis.
Funding mechanism: Non-dilutive SBIR funding since 2014.
-
PATHWAY TO COMMERCIALIZATION
-
PATHWAY TO COMMERCIALIZATION
ITi preclinical development of biologics fits into the Proof-of-Principle (POC) and Pre-IND space (IND enabling studies). Once the IP is secured, ITi seeks strategic alliances (for example, a license) with interested parties that have the capability to commercialize the product. Each new Patent or License either becomes the foundation of a new company or, if it fits within a pipeline of products of an existing company, a licensing agreement is established between the parties.
Parties interested in Strategic Alliances please contact us.
-
FINANCIAL CONFLICT OF INTEREST POLICY
Issued July 31, 2025 | Version 01
Policy Statement
Immuno Technologies, Inc. (Immuno) is committed to maintaining the integrity, objectivity, and transparency of its research activities. The company has established a Financial Conflict of Interest (FCOI) Policy to ensure that the design, conduct, and reporting of research are protected from bias arising from investigators' financial interests.
The policy implements the requirements of the U.S. Public Health Service (PHS) regulations on promoting objectivity in research, including 42 CFR Part 50, Subpart F, and 45 CFR Part 94. It applies to investigators participating in PHS-funded research, including research supported by the National Institutes of Health (NIH).
Disclosure of Financial Interests
All investigators responsible for the design, conduct, or reporting of PHS/NIH-funded research must disclose significant financial interests (SFIs) related to their institutional responsibilities. This includes applicable financial interests held by investigators' spouses and dependent children.
Disclosures are required at the time of application for research funding, at least annually during the period of an NIH award, and within 30 days of acquiring or discovering a new significant financial interest. Disclosure requirements also extend to applicable foreign financial interests and reimbursed or sponsored travel.
Review and Management of Financial Conflicts of Interest
Immuno's Designated Official is responsible for reviewing disclosures and determining whether a significant financial interest constitutes a financial conflict of interest.
Where a conflict is identified, Immuno will implement appropriate measures to manage, reduce, or eliminate the conflict. These may include public disclosure, independent monitoring, modification of research activities, or changes in personnel responsibilities. Identified conflicts will be reported to the appropriate funding agency in accordance with applicable regulations.
Training and Compliance
Investigators participating in PHS/NIH-funded research must complete FCOI training before engaging in the research and at least every four years thereafter. Additional training is required under circumstances specified in the policy, including relevant policy revisions or investigator noncompliance.
Immuno maintains procedures for monitoring compliance, addressing identified conflicts, fulfilling reporting requirements, and retaining relevant records.
Public Accessibility
Immuno makes its complete FCOI Policy publicly available in accordance with PHS/NIH requirements.
Information concerning qualifying financial conflicts of interest held by senior/key personnel involved in NIH-funded research will be made available in response to written requests within five business days, as specified in the policy.
Full Policy: Immuno Technologies, Inc. Financial Conflict of Interest Policy (PDF, July 2025)
Point of Contact
For questions concerning the FCOI Policy, requests for information, or disclosure of financial interests, please contact:
Maria Gomes-Solecki
Immuno Technologies, Inc.
Partnerships
